Survivin mediates aberrant hematopoietic cell proliferation induced by ITD-Flt3 and regulates development of ITD-Flt3+ acute leukemia, suggesting that antagonizing Survivin may provide therapeutic benefit for patients with AML expressing ITD-Flt3 [14]. Here, BIRC5 is linked to acute leukemia.